CDDI

About Competitive Drug Development International Ltd.

 

CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.

 

Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.

 

Our working method is hands-on, not just consulting, which means, we don’t just advise you, but actively implement the strategies and plans that we formulate with you. For more information please visit www.cddi.co.

Website:
www.cddi.co
Company type
Dr Grahaem Brown
Dr Grahaem Brown
Managing Partner 
Ms Eva Hurst
Ms Eva Hurst
Partner 

Crescendo Biologics

Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.

VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.  

Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.

Company type
Dr Matthew Roe
Chief Business Officer 

CrystecPharma

CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Crystec SCF technologies can be applied to both small drug molecules and biomolecules.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.

We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large moilecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.

Company type
Dr Catherine Hunter

Datatrial Limited

Datatrial is an eClinical solutions company, providing comprehensive data management, bio-statistical and consulting services. We have our own proprietary software, nowEDC™ which has been deployed globally in Phase I to Phase III trials.  Our ethos is to collaborate with our customers to find and offer solutions that will assist in the achievement of clinical objectives.

 

Company type
Mr Lewis Baird
Mr Lewis Baird
Business Development Manager 

Desktop Genetics

Desktop Genetics is a UK-based biotech software company dedicated to making commercial R&D more productive and cost efficient. We develop bespoke workflow tools to simplify the most time-consuming and frustrating challenges facing molecular biologists in genome-editing, disease biology, antibody engineering, cell line development, functional genomics and protein production.

Each tool comprises a collection of functional modules, powered by our proprietary DNA Search Engine technology. To date, modules have let users search for DNA sequences across the world, create an in-lab knowledge base with persistent DNA and oligo sequence data, automatically calculate optimal cloning strategies and repurpose existing DNA. Easily deployed with your existing DNA sequence databases, our technology streamlines and automates workflows so that your skilled personnel can focus on the critical research that drives your business.

Founded by scientists and researchers, our team is experienced with the technical, operational and financial challenges facing molecular biology laboratories today. We are fluent in the languages of biology, programming, and R&D operations, ensuring your needs are translated into a superior business and research tool. We look to partner with life science companies to deploy existing modules and develop new ones from the ground up. Get in touch with us today to discuss how we can help make your DNA work for you.

Contact: Victor Dillard, COO - victord@deskgen.com

Website:
www.deskgen.com
Company type
Mr Victor Dillard
Mr Victor Dillard
COO and Founder 

Domainex

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.

Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.

 Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 for both oncology and inflammation and a number of epigenetics related lysine methyltransferases, including G9a

Company type
Dr Eddy Littler
Chief Executive Officer 
Dr Joanne McCudden
Head of Business Development 

e-therapeutics

e-Therapeutics is an AIM-listed biotechnology company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is focused in cancer and disorders of the nervous system. The firm has two drugs in the clinic: ETS2101, which is in phase I trials for cancer; and ETS6103, which is in phase II trials for major depressive disorder. e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company please visit www.etherapeutics.co.uk.  

Company type
Dr Daniel Elger
Dr Daniel Elger
Chief Financial Officer 

Epistem Ltd

Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.

The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.

The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.

Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.

Company type
Dr Andrew Carnegie
Business Development Manager 
Mr Jeremy Kamaluddin
Business Development Director 

Genetic Microdevices

The company develops companion diagnostic tests and biomarker discovery platforms based on its unique analytical technology, the CycloChipTM. The tests come in the form of disposable cartridges specific to desired applications. 

Direct comparative studies, have shown that the technology is between 30x-270x times faster, with over 10x higher resolution and 2000x more sensitive than competing top of the range analytical instruments.

The fact that this performance can be achieved in disposable devices that can be flexibly customised to different diagnostic and analytical applications, makes this device very attractive diagnostic companies and CROs.

GMD is looking for end-users of the technology to tailor the disposable cartridges to their specific needs. 

The CycloChipTM performs the tests based on a unique molecular separation method that allows for unprecedented throughput, sensitivity and resolution. Unlike chemistry based diagnostic companions, our system is not limited to a single molecule or a small number of molecules, but rather it can be tailored to an endless number of different molecular tests, tailored to the needs of our pharmaceutical or diagnostic client.

The GMD system can be applied to both proteomic and genomic analyses.

GMD is looking for a partner/end user to out license its technology and at the same time develop its product portfolio driven by the specific needs of the end-user. The latter could be a pharmaceutical company with internal R&D or a diagnostic company. 

GMD is based at Kingston University, London. It's technology has been awarded multiple prestigeous grants, from the London Development Agency and Technology Strategy Board.

Dr Dimitris Sideris
Chief Executive Officer 

Glythera Ltd

Glythera is an emerging biotechnology company specializing in the development of next generation biotherapeutics through the application of its advanced proprietary conjugation and glycosylation technologies.

Located in the North East of the UK with its dedicated bioprocessing and chemistry development laboratories at Newcastle University, Glythera is positioned as a critical partner in any development program centred on its PermaLink™ and PermaCarb™ technologies.

Our PermaLink™ platform supports highly selective site specific conjugation whilst demonstrating significantly increased stability with our core focus being in the development of enhanced Antibody Drug Conjugates and bi-specifics.

Glythera’s PermaCarb™ technology allows direct substitution of endogenous glycan’s or correction of micro-heterogeneity using stable analogues to improve bioavailability and efficacy and has been demonstrated in a range of next generation biotherapeutics.

Our Mission is to enable improved clinical regimes through the creation of the next generation of safe, efficacious biotherapeutic products in oncology and therapeutic indications.

 

Website:
www.glythera.com
Company type
Dr David Simpson
Chief Operating Officer